Hoi Shuen Solina Holly Chau
Hoi Shuen Solina Holly Chau's purchase track record
Hoi Shuen Solina Holly Chau has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/30/2022 | NAGE | $1.20M | +36.6% | +24.4% | +14.6% |
| 6/16/2022 | NAGE | $100K | -10.4% | -2.4% | +6.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Celsius Holdings sees analyst coverage and turnaround focus. Recent coverage of Celsius includes a lowered price target to $35 from TD Cowen while the consensus analyst target stays near $42. Analysts note a possible recovery but limited upside, pointing to recent acquisitions and the Alani Nu brand as part of a turnaround plan. A separate note mentions Boston Beer’s upcoming earnings, which could influence the broader beverage sector in which Celsius operates.
Transaction History
| NAGE | ▲ Buy | Open Market | 11,408,715 | — | 8/20/2024 | View on chart |
| CELH | ▼ Sell | Open Market | 300,000 | $52.5M | 8/15/2023 | View on chart |
| CELH | ▼ Sell | Open Market | 350,976 | $50.0M | 6/14/2023 | View on chart |
| CELH | ▼ Sell | Open Market | 514,933 | $50.0M | 5/2/2023 | View on chart |
| CELH | ▼ Sell | Open Market | 554,017 | $50.0M | 3/6/2023 | View on chart |
| NAGE | ▲ Buy | Open Market | 960,000 | $1.2M | 9/30/2022 | View on chart |
| NAGE | ▲ Buy | Open Market | 60,037 | $100K | 6/16/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
NAGE linked to new preclinical study on CD38 and NAD+ decline
A new preclinical study identified CD38 as a driver of age‑related NAD+ decline and showed that nicotinamide riboside can improve pregnancy outcomes in animal models. The research also reported lower NAD+ levels in placental tissue from older mothers. Niagen Bioscience clarified that it did not conduct, fund, or design the study and that the NR used was not its proprietary Niagen ingredient. The findings relate to the company’s focus on NAD+‑boosting products and may draw attention to its pipeline.
NAGE linked to new preclinical study on CD38 and NAD+ decline. A new preclinical study identified CD38 as a driver of age‑related NAD+ decline and showed that nicotinamide riboside can improve pregnancy outcomes in animal models. The research also reported lower NAD+ levels in placental tissue from older mothers. Niagen Bioscience clarified that it did not conduct, fund, or design the study and that the NR used was not its proprietary Niagen ingredient. The findings relate to the company’s focus on NAD+‑boosting products and may draw attention to its pipeline.